Citations

Clear

426 citation(s) found for "ST, Reza".

The prognostic value of artificial intelligence to predict cardiac amyloidosis in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement
Pereyra, Milagros , Mahmoud, Ahmed K., Galasso, Francesca , Killian, Michael , Suppah, Mustafa, Kenyon, Courtney , Koepke, Laura, Padang, Ratnasari , Sweeney, John P., Fortuin, F. David , Eleid, Mackram F. , Steidley, D. Eric , Scott, Luis R. , Grogan, Martha , Rosenthal, Julie , Mahmoud, Ahmed , Pereyra, Milagros , Killian, Michael E, Kenyon, Courtney R, Koepke, Laura M, Padang, Ratnasari , Steidley, David E, Lopez-Jimenez, Francisco , Rosenthal, Julie L., Mahmoud, Ahmed K , Farina, Juan M. , Scalia, Isabel G. , Chao, Chieh‐Ju , Sell‐Dottin, Kristen , Fonseca, Rafaël , López-Jiménez, Francisco , Attia, Zachi I. , Dispenzieri, Angela , Arsanjani, Reza

Mayo Clinic

European Heart Journal - Digital Health | March 11, 2024 | Volume: 5 | Issue: 3 | Pages: 295-302

10.1093/ehjdh/ztae022 | PMID 38774378 Get It

Abstract Aims Cardiac amyloidosis (CA) is common in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). Cardiac amyloidosis has poor outcomes, and its assessment in all TAVR patients is costly and challenging. Electrocardiogram (ECG) artificial intelligence (AI) algorithms that screen for CA may be useful to identify at-risk patients. Methods and results In this retrospective analysis of our institutional National Cardiovascular Disease Registry (NCDR)-TAVR database, patients undergoing TAVR between January 2012 and December 2018 were included. Pre-TAVR CA probability was analysed by an ECG AI predictive model, with >50% risk defined as high probability for CA. Univariable and propensity score covariate adjustment analyses using Cox regression were performed to compare clinical outcomes between patients with high CA probability vs. those with low probability at 1-year follow-up after TAVR. Of 1426 patients who underwent TAVR (mean age 81.0 ± 8.5 years, 57.6% male), 349 (24.4%) had high CA probability on pre-procedure ECG. Only 17 (1.2%) had a clinical diagnosis of CA. After multivariable adjustment, high probability of CA by ECG AI algorithm was significantly associated with increased all-cause mortality [hazard ratio (HR) 1.40, 95% confidence interval (CI) 1.01–1.96, P = 0.046] and higher rates of major adverse cardiovascular events (transient ischaemic attack (TIA)/stroke, myocardial infarction, and heart failure hospitalizations] (HR 1.36, 95% CI 1.01–1.82, P = 0.041), driven primarily by heart failure hospitalizations (HR 1.58, 95% CI 1.13–2.20, P = 0.008) at 1-year follow-up. There were no significant differences in TIA/stroke or myocardial infarction. Conclusion Artificial intelligence applied to pre-TAVR ECGs identifies a subgroup at higher risk of clinical events. These targeted patients may benefit from further diagnostic evaluation for CA.
Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts
Asumda, Faizal Z., Campbell, Nellie A. , Hassan, Mohamed A. , Fathi, Reza , Rico, Daniella F. Vasquez, Kiem, Melanie, Vang, Ethan V., Kim, Yo Han , O’Brien, Daniel R. , Buhrow, Sarah A. , Ben-Yair, Vered Katz , Levitt, Mark L. , Leiting, Jennifer L. , Abdelrahman, Amro M. , Zhu, Xinli, Lucien, Fabrice , Truty, Mark J. , Roberts, Lewis R. , O'Brien, Daniel R, Levitt, Mark L , Abdelrahman, Amro M , Lucien, Fabrice , Roberts, Lewis R , Campbell, Nellie A , Luo, Xin , Reid, Joel M. , Moore, Michael J.

Mayo Clinic

Cancers | March 5, 2024 | Volume: 16 | Issue: 5 | Pages: 1050

10.3390/cancers16051050 | PMID 38473407 Get It

Upamostat is an orally available small-molecule serine protease inhibitor that is a highly potent inhibitor of trypsin 1, trypsin 2, trypsin 3 (PRSS1/2/3), and the urokinase-type plasminogen activator (uPA). These enzymes are expressed in many cancers, especially during tissue remodeling and subsequent tumor cell invasion. Opaganib (ABC294640), a novel, orally available small molecule is a selective inhibitor of the phosphorylation of sphingosine to sphingosine-1-phosphate (S-1-P) by sphingosine kinase 2 (SPHK2). Both sphingosine kinase 1 (SPHK1) and SPHK2 are known to regulate the proliferation-inducing compound S-1-P. However, SPHK2 is more critical in cancer pathogenesis. The goal of this project was to investigate the potential antitumor effects of upamostat and opaganib, individually and in combination, on cholangiocarcinoma (CCA) xenografts in nude mice. PAX165, a patient-derived xenograft (PDX) from a surgically resected CCA, expresses substantial levels of SPHK2, PRSS1, PRSS2, and PRSS3. Four groups of 18 mice each were treated with upamostat, opaganib, both, or vehicle. Mouse weights and PAX165 tumor volumes were measured. Tumor volumes in the upamostat, opaganib, and upamostat plus opaganib groups were significantly decreased compared to the control group.
Meta‐analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease
Zamani, Mohammad , Alizadeh‐Tabari, Shaghayegh , Ananthakrishnan, Ashwin N. , Talley, Nicholas J. , Talley, Nicholas J. , Murad, Mohammad Hassan, Ananthakrishnan, A N , Malekzadeh, Reza , Zamani, Mohammad , Murad, M. Hassan

Mayo Clinic

Alimentary Pharmacology & Therapeutics | February 19, 2024 | Volume: 59 | Issue: 8 | Pages: 918-927

10.1111/apt.17919 | PMID 38372406 Get It

SummaryBackgroundStudies exploring the association between inflammatory bowel disease (IBD) and pancreatic cancer have reported inconsistent results.AimsTo provide a comprehensive overview of the risk of pancreatic cancer development in patients with IBD.MethodsWe searched Embase, PubMed, Scopus and ProQuest from inception to 31 October 2023. We included population‐based cohort studies examining the risk of incident pancreatic cancer in adult patients with IBD compared to the non‐IBD population. We also retrieved Mendelian randomisation (MR) studies investigating the relationship of IBD with pancreatic cancer risk. We conducted random‐effects meta‐analyses and provided pooled relative risks (RRs) with 95% confidence intervals (CIs).ResultsWe included 13 studies. Among 11 cohort studies, the risk of developing pancreatic cancer increased by 79% in patients with IBD (RR = 1.79 [95% CI: 1.16–2.75]; I2 = 95.7%). Patients either with Crohn's disease (RR = 1.42 [95% CI: 1.24–1.63]) or ulcerative colitis (RR = 1.50 [95% CI: 1.17–1.92]) had increased risk (p for interaction = 0.72). The annual incidence of pancreatic cancer potentially attributable to IBD increased by 55 cases (95% CI: 17–103) per million. Two MR studies demonstrated that genetic liability to IBD was associated with an increased risk of pancreatic cancer.ConclusionsOur results suggest a moderate increase in the risk of pancreatic cancer in patients with IBD, which may be further heightened by genetic predisposition to IBD. The increased risk of pancreatic cancer is probably similar in Crohn's disease and ulcerative colitis.
Abstract WP8: To Report the Visual Outcome and Safety Profile in Patients With Branch Retinal Artery Occlusion (BRAO) That Received Intravenous (IV) and Intra-Arterial (IA) Thrombolysis
Bavarsad, Reza, Dumitrașcu, Oana , Shahjouei, Shima

Mayo Clinic

Stroke | February 1, 2024 | Volume: 55 | Issue: Suppl_1 | Pages: No page available

10.1161/str.55.suppl_1.wp8 Get It

Introduction: Branch retinal artery occlusion (BRAO) results from the blood flow compromise in of the branches of the central retinal artery. Data is limited on the outcome of patients with BRAO who received thrombolytic therapy as acute phase management protocol. Method: This study is a sub-analysis of our prior systematic review and meta-analysis on the visual outcome of patients with retinal artery occlusion who received intra-arterial (IA) or intra-venous (IV) thrombolytics within the first 24 hours. PubMed, Cochrane Library, ScienceDirect via Elsevier, International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, and Trip Medical Database were systematically searched with a predefined protocol to record the change in the visual acuity (VA) after thrombolytic therapy. We limited this study to the patients with BRAO who received urokinase (UK) or tissue plasminogen activator (tPA). Results: Among 1153 identified studies, 771 patients with retinal artery occlusion received thrombolytic therapy. BRAO was observed in 19 patients (2.5%, mean age: 65 years). IAT-tPA was administered in 8 (42.1%), IVT-tPA in 7 (36.8%), and IVT-UK in 4 (21.1%). Median time from the onset of visual change to thrombolysis was 6.0 [4.5-10.5] hours. Patients had mean baseline logarithm of the Minimum Angle of Resolution (logMAR) of 0.9±0.8. VA improvement of ≥0.1 logMAR (one Snellen line) was seen among 17 (89.5%), VA improvement of ≥0.3 logMAR (three Snellen lines) among 13 (68.4%), and a final VA of 20/100 or better among 16 (84.2%). One (5.3%) patient had intra-ocular hemorrhage post thrombolysis. Conclusion: Compared to central retinal artery occlusion, patient with branched retinal occlusion have better visual recovery following IA or IV thrombolysis. These results can be affected by the small number of the patients in this study.
Identifying the Causes of Unexplained Dyspnea at High Altitude Using Normobaric Hypoxia with Echocardiography
Stepánek, Jan , Farina, Juan M. , Mahmoud, Ahmed , Alsidawi, Said , Barry, Timothy , Pereyra, Milagros , Scalia, Isabel G. , Abbas, Mohammed Tiseer , Wraith, Rachel, Brown, Lisa , Radavich, Michael S., Curtisi, Pamela J., Hartzendorf, Patricia C., Lasota, Elizabeth M., Umetsu, Kyley N., Karlson, Kristin E., Breznak, Karen K., Fortuin, David, Lester, Steven J., Arsanjani, Reza , Alsidawi, Said , Barry, Timothy , Pereyra, Milagros , Scalia, Isabel G , Abbas, Mohammed Tiseer , Wraith, Rachel E, Brown, Lisa S, Peterson, Jill M, Breznak, Karen, Fortuin, David F, Arsanjani, Reza , Farina, Juan M , Mahmoud, Ahmed K , Stepánek, Jan , Chao, Chieh‐Ju , Peterson, Jill M.

Mayo Clinic

Journal of Imaging | January 31, 2024 | Volume: 10 | Issue: 2 | Pages: 38

10.3390/jimaging10020038 | PMID 38392086 Get It

Exposure to high altitude results in hypobaric hypoxia, leading to physiological changes in the cardiovascular system that may result in limiting symptoms, including dyspnea, fatigue, and exercise intolerance. However, it is still unclear why some patients are more susceptible to high-altitude symptoms than others. Hypoxic simulation testing (HST) simulates changes in physiology that occur at a specific altitude by asking the patients to breathe a mixture of gases with decreased oxygen content. This study aimed to determine whether the use of transthoracic echocardiography (TTE) during HST can detect the rise in right-sided pressures and the impact of hypoxia on right ventricle (RV) hemodynamics and right to left shunts, thus revealing the underlying causes of high-altitude signs and symptoms. A retrospective study was performed including consecutive patients with unexplained dyspnea at high altitude. HSTs were performed by administrating reduced FiO2 to simulate altitude levels specific to patients’ history. Echocardiography images were obtained at baseline and during hypoxia. The study included 27 patients, with a mean age of 65 years, 14 patients (51.9%) were female. RV systolic pressure increased at peak hypoxia, while RV systolic function declined as shown by a significant decrease in the tricuspid annular plane systolic excursion (TAPSE), the maximum velocity achieved by the lateral tricuspid annulus during systole (S’ wave), and the RV free wall longitudinal strain. Additionally, right-to-left shunt was present in 19 (70.4%) patients as identified by bubble contrast injections. Among these, the severity of the shunt increased at peak hypoxia in eight cases (42.1%), and the shunt was only evident during hypoxia in seven patients (36.8%). In conclusion, the use of TTE during HST provides valuable information by revealing the presence of symptomatic, sustained shunts and confirming the decline in RV hemodynamics, thus potentially explaining dyspnea at high altitude. Further studies are needed to establish the optimal clinical role of this physiologic method.
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
An, Zesheng , Gicobi, Joanina K. , Xu, Tianxiao , Harrington, Susan M. , Hirdler, Jacob, Lohse, Christine M. , Pessoa, Rodrigo Rodrigues , Sharma, Vidit , Thompson, Houston R., Leibovich, Bradley C. , Hsu, Michelle A. , Zhang, Henan , Pavelko, Kevin D. , Hirdler, Jacob B. , Nabavizadeh, Reza , Thompson, Houston, Dong, Haidong , Lucien, Fabrice

Mayo Clinic

Journal of Clinical Oncology | January 29, 2024 | Volume: 42 | Issue: 4_suppl | Pages: 458-458

10.1200/jco.2024.42.4_suppl.458 Get It

458 Background: Immune checkpoint inhibitors (ICI) targeting PD-1/PD-L1 axis has revolutionized the therapeutic landscape of patients with advanced and locally advanced renal cell carcinoma (RCC). However, complete response rates remain low and there is a need for novel therapeutic options for ICI-resistant and refractory RCC. Our group has generated a novel humanized anti-PD-L1 antibody, called H1A, that induces PD-L1 degradation preventing not only its interaction with PD-1 but also inhibiting pro-tumorigenic intracellular signaling. In this study, we compared the antitumor activity of H1A with FDA-approved ICI using patient-derived immune cells and humanized mouse tumor models. Methods: In vivo antitumor activity of H1A and atezolizumab (ATZ) was compared in three humanized PD-1/PD-L1 mouse tumor models with different immunogenicity (E0771:high, MC38:moderate, B16-F10:poor). Peripheral blood mononuclear cells (PBMC) were isolated from 14 RCC patients undergoing with nephrectomy. PBMC were treated with H1A, nivolumab (NIV), atezolizumab (ATZ) and pembrolizumab (PEM) to evaluate their efficacy in inducing tumor cell death in an ex-vivo cytotoxicity assay. Mass cytometry was employed to determine the impact of H1A and atezolizumab on the PBMC profile. Results: MC38 tumors showed moderate response to both H1A and ATZ which was abrogated by CD8 T cell depletion. In E0771 tumors, higher percentage of complete responders was observed with H1A compared to ATZ and E0771 rechallenge revealed memory antitumor immunity with complete rejection of tumors. Patient-derived PBMC treated with H1A showed superior tumor cell killing compared to NIV, PEM and ATZ (p<0.01). While H1A treatment of PBMC induced expansion of effector NK and CD8 T cells (GZMB+ T-bet+), ATZ treatment led to enrichment of Tregs (CD25+,Foxp3+) expressing inhibitory markers PD-1 and LAG-3. Conclusions: H1A demonstrated superior antitumor activity compared to FDA-approved ICI which lays the ground for clinical testing of H1A as a next-generation immune checkpoint inhibitor for the treatment of renal cell carcinoma.
Venous tumor thrombus destinations in patients with renal cell carcinoma.
Pessoa, Rodrigo Rodrigues , Cheville, John C. , Lohse, Christine M. , Costello, Brian A. , Thompson, Houston R., Boorjian, Stephen A. , Leibovich, Bradley C. , Sharma, Vidit , Nabavizadeh, Reza , Lucien, Fabrice , Thompson, Houston

Mayo Clinic

Journal of Clinical Oncology | January 29, 2024 | Volume: 42 | Issue: 4_suppl | Pages: 381-381

10.1200/jco.2024.42.4_suppl.381 Get It

381 Background: Venous tumor thrombus (VTT) is associated with worse oncologic outcomes in clear cell renal cell carcinoma (ccRCC). It is unknown if VTT and pulmonary embolism (PE) predispose patients to pulmonary metastasis. Methods: We queried our institutional registry for ccRCC patients undergoing radical nephrectomy (1970-2019). Cox proportional hazards regression models, adjusting for factors associated with ccRCC progression, were used to determine if VTT and PE were associated with pulmonary metastasis. Results: Of 3,410 patients studied, 1,025 (30%) had VTT, and patients with VTT were more likely to present with pulmonary metastasis at nephrectomy (20% vs 7%, p<0.001). Within the VTT subset, level of VTT was not significantly associated with pulmonary metastasis at nephrectomy (p=0.3). For all patients who had metastatic disease at nephrectomy (n=643), pulmonary metastasis was more common in those with VTT versus those without VTT (68% vs 51%, p<0.001). Excluding patients with pulmonary metastasis at nephrectomy, on multivariable analysis, VTT remained associated with post-nephrectomy pulmonary metastasis (hazard ratio (HR) 1.31, p<0.001) without a notable difference in HRs between renal vein (1.27) and caval (1.38) VTT. Presence of PE in the setting of VTT was associated with increased pulmonary metastasis post-nephrectomy (HR 2.31, p<0.001). Conclusions: VTT is associated with disproportionately increased pulmonary metastasis at presentation and post-nephrectomy in ccRCC patients. Further, the presence of PE at nephrectomy for VTT was associated with increased pulmonary metastasis post-nephrectomy. These results support a metastatic predilection of ccRCC with VTT to the lungs.
Comparative analysis of Attention-based CNN andViT for processing ECG image data in joint fusion
Thakur, Arjun, Holmes, David R. , Fortuin, David, Banerjee, Imon , Banerjee, Imon , Agasthi, Pradyumna , Chao, Chieh‐Ju , Farina, Juan M. , Holmes, David R. , Arsanjani, Reza

Mayo Clinic

No container title available | January 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3892330/v1 Get It

Abstract Percutaneous Coronary Intervention (PCI) is a widely utilized standard ofcare and efficacious intervention in the management of coronary artery disease,improving prognosis and symptoms for many patients. Prediction of post-PCIoutcomes contributes to effective patient management and quality improvementinitiatives in healthcare. Our study focuses on comparative performance analysisfor state-of-the-art vision transformer (ViT) and convolutional neural network(CNN) on multimodal data analysis in a joint fusion framework. We integrateimages of electrocardiogram (ECG) data and tabular electronic health records(EHR) to predict 3 clinically relevant post-PCI (6 months) endpoints - heart failure hospitalization, all-cause mortality, and ischemic stroke. To design a comparativemodel for ViT, we proposed a new joint fusion architecture that consistsof a convolutional neural network (CNN) with a convolutional block attentionmodule (CBAM). The learned representations are combined at an intermediatelayer followed by processing these representations using a fully connectedlayer. The proposed model demonstrates excellent performance with the highestAUROC scores of 0.849, 0.913, and 0.794 for predicting heart failure hospitalization,all-cause mortality, and stroke, respectively. Surpassing the baseline EHRmodel and ViT, the proposed CNN+CBAM fusion model showcases superiorpredictive capabilities for heart failure prediction.
An Integrated 3-Dimentional Navigation System Increases the Accuracy, Efficiency, and Safety of Percutaneous Thoracolumbar Pedicle Screw Placement in Minimally Invasive Approaches: A Randomized Cadaveric Study
Lakomkin, Nikita , Eastlack, Robert K. , Uribe, Juan S. , Ryu, Stephen I. , Kretzer, Ryan M., Mimran, R, Holman, Paul J. , Veeravagu, Anand , Hassanzadeh, Hamid , Johnson, Michele M., Sullivan, Linda, Mundis, Gregory M. , Park, Paul , Hassanzadeh, Hamid Reza , Clark, Allan

Mayo Clinic

Global Spine Journal | January 2, 2024 | Volume: 15 | Issue: 2 | Pages: 1099-1105

10.1177/21925682231224394 | PMID 38165219 Get It

Study Design Cadaveric study. Objectives The purpose of this study was to compare a novel, integrated 3D navigational system (NAV) and conventional fluoroscopy in the accuracy, efficiency, and radiation exposure of thoracolumbar percutaneous pedicle screw (PPS) placement. Methods Twelve skeletally mature cadaveric specimens were obtained for twelve individual surgeons. Each participant placed bilateral PS at 11 segments, from T8 to S1. Prior to insertion, surgeons were randomized to the sequence of techniques and the side (left or right). Following placement, a CT scan of the spine was obtained for each cadaver, and an independent reviewer assessed the accuracy of screw placement using the Gertzbein grading system. Outcome metrics of interest included a comparison of breach incidence/severity, screw placement time, total procedure time, and radiation exposure between the techniques. Bivariate statistics were employed to compare outcomes at each level. Results A total of 262 screws (131 using each technique) were placed. The incidence of cortical breaches was significantly lower with NAV compared to FG (9% vs 18%; P = .048). Of breaches with NAV, 25% were graded as moderate or severe compared to 39% in the FG subgroup ( P = .034). Median time for screw placement was significantly lower with NAV (2.7 vs 4.1 min/screw; P = .012), exclusive of registration time. Cumulative radiation exposure to the surgeon was significantly lower for NAV-guided placement (9.4 vs 134 μGy, P = .02). Conclusions The use of NAV significantly decreased the incidence of cortical breaches, the severity of screw breeches, screw placement time, and radiation exposure to the surgeon when compared to traditional FG.
Emerging Antibody-Drug Conjugate Therapies and Targets for Metastatic Renal Cell Carcinoma
Gottlich, Harrison C., Pessoa, Rodrigo Rodrigues , Mahmoud, Ahmed , Garg, I. D. , Orme, Jacob J. , Costello, Brian A. , Cheville, John C. , Mahmoud, Ahmed M , Nabavizadeh, Reza , Dumbravă, Mihai , Garg, Ishita, Lucien, Fabrice

Mayo Clinic

Kidney Cancer | December 29, 2023 | Volume: 7 | Issue: 1 | Pages: 161-172

10.3233/kca-230012 Get It

Background: Approximately 30% of renal cell carcinoma (RCC) cases present with de novo metastatic disease, while 20% to 30% of those with localized disease will develop metastases following surgical resection. Various drug classes have been investigated to treat RCC, including cytokine-based therapies, small molecule Vascular Endothelial Growth Factor (VEGF) tyrosine kinase inhibitors (TKIs) and antibody-based therapies. Up to 58% of patients fail to respond to primary immune checkpoint inhibitor (ICI) therapy, and nearly all initial responders experience disease progression due to the development of secondary resistance. Consequently, novel treatment options are being investigated. Objective: Review the rapidly evolving ADC therapeutic landscape in metastatic RCC including recent trials, emerging ADCs targets, and future directions for ADCs in the treatment of advanced RCC. Methods: Literature review using the MEDLINE database on important trials and presentations from the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO) conferences. Key words used included “renal cell carcinoma,” “RCC,” “metastatic RCC,” “advanced RCC,” “antibody-based therapies,” “immunotherapy,” “clinical trials,” and “emerging drugs.” Specifically for review of ADCs in RCC, the following search string was used with additional review of bibliographies from retrieved papers: “((antibody drug conjugate) OR (antibody-dependent cellular cytotoxicity) OR (chimeric antigen receptor)) AND ((kidney cancer) OR (renal cell carcinoma))”. Results: Several promising targets including MMP14, EGFR, MCT4, CA9, MET, CDH13, B7-H3, and PSMA were identified with relevant preclinical and clinical studies reviewed. Conclusions: While ADCs therapeutics have not shown benefit to date for renal cell carcinoma, there are ample promising candidates and targets for future research.